AbbVie 2013 Annual Report Download - page 126

Download and view the complete annual report

Please find page 126 of the 2013 AbbVie annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 176

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164
  • 165
  • 166
  • 167
  • 168
  • 169
  • 170
  • 171
  • 172
  • 173
  • 174
  • 175
  • 176

committee and the participants. The investment committee must solicit voting instructions from the
participants and follow the voting instructions it receives. The investment committee may use its own
discretion with respect to those shares of AbbVie common stock for which no voting instructions are
received.
SEPARATION OF ABBVIE FROM ABBOTT LABORATORIES
On January 1, 2013, AbbVie became an independent company as a result of the distribution by
Abbott Laboratories (‘‘Abbott’’) of 100% of the outstanding common stock of AbbVie to Abbott’s
shareholders (the ‘‘Separation’’). Each Abbott shareholder of record as of the close of business on
December 12, 2012 (the ‘‘Record Date’’) received one share of AbbVie common stock for each Abbott
common share held as of the Record Date. AbbVie was incorporated in Delaware on April 10, 2012
and is comprised of Abbott’s former research-based pharmaceuticals business. AbbVie’s Registration
Statement on Form 10 was declared effective by the U.S. Securities and Exchange Commission (‘‘SEC’’
or the ‘‘Securities and Exchange Commission’’) on December 7, 2012. AbbVie’s common stock began
trading ‘‘regular-way’’ under the ticker symbol ‘‘ABBV’’ on the New York Stock Exchange on January 2,
2013. For additional information, please see AbbVie’s Information Statement, which is attached as
Exhibit 99.1 to AbbVie’s Current Report on Form 8-K filed with the SEC on January 2, 2013.
CORPORATE GOVERNANCE MATERIALS
AbbVie’s corporate governance guidelines with the outline of directorship qualifications; director
independence guidelines; code of business conduct; and audit committee, compensation committee,
nominations and governance committee, and public policy committee charters are all available in the
corporate governance section of AbbVie’s investor relations website at www.abbvieinvestor.com.
3